Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. BJS 2017; 104: 600-607.
Published: 8th February 2017
Authors: D. Ansari, M. Bauden, S. Bergström, R. Rylance, G. Marko‐Varga, R. Andersson et al.
The size of pancreatic ductal adenocarcinoma (
Patients diagnosed with
Some 58 728 patients were included. There were 187 patients (0·3 per cent) with a tumour size of 0·5 cm or less, in whom the rate of distant metastasis was 30·6 per cent. The probability of tumour dissemination was associated with tumour size at the time of diagnosis. The association between survival and tumour size was linear for patients with localized tumours, but stochastic in patients with regional and distant stages. In patients with resected tumours, increasing tumour size was associated with worse tumour‐specific survival, whereas size was not associated with survival in patients with unresected tumours. In the adjusted Cox regression analysis, the death rate increased by 4·1 per cent for each additional 1‐cm increase in tumour size.
Pancreatic cancer has a high metastatic capacity even in small tumours. The prognostic impact of tumour size is restricted to patients with localized disease.Read more
You may also be interested in
Survival following liver transplantation for liver‐only colorectal metastases compared with hepatocellular carcinoma.
Authors: S. Dueland, A. Foss, J. M. Solheim, M. Hagness, P.‐D. Line
Notes: Valid treatment option for colorectal liver metastases
Propensity score‐matched comparison of oncological outcomes between laparoscopic and open distal pancreatic resection.
Authors: M. Raoof, P. H. G. Ituarte, Y. Woo, S. G. Warner, G. Singh, Y. Fong et al.
Notes: No difference in survival
Authors: M. G. Keane, A. Shamali, L. N. Nilsson, A. Antila, J. Millastre Bocos, M. Marijinissen Van Zanten et al.
Notes: Low risk in small, asymptomatic mucinous cystic neoplasms
Authors: A. ten Hove, V. E. de Meijer, J. B. F. Hulscher, R. H. J. de Kleine
Notes: Choledochal cysts should be resected
Authors: M. Gelli, M. A. Allard, O. Farges, C. Paugam‐Burtz, J. Y. Mabrut, J. M. Regimbeau et al.
Notes: No increased risk
Meta‐analysis of delayed gastric emptying after pylorus‐preserving versus pylorus‐resecting pancreatoduodenectomy. BJS 2018; 105: 339-349.
Authors: U. Klaiber, P. Probst, O. Strobel, C. W. Michalski, C. Dörr‐Harim, M. K. Diener et al.
Notes: No difference
Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation. BJS 2018; 105: 328-338.
Authors: G. Vanella, S. Crippa, L. Archibugi, P. G. Arcidiacono, G. Delle Fave, M. Falconi et al.
Notes: Low disease‐related mortality
Authors: P. Studer, T. Horn, A. Haynes, D. Candinas, V. M. Banz
Randomized clinical trial
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. BJS 2018; 105: 192-202.
Authors: T. Ebata, S. Hirano, M. Konishi, K. Uesaka, Y. Tsuchiya, M. Ohtsuka et al.
Notes: No advantage
Circulating tumour cells and DNA as liquid biopsies in gastrointestinal cancer. BJS 2018; 105: e110-e120.
Authors: O. Nordgård, K. Tjensvoll, B. Gilje, K. Søreide
Notes: The inner space frontier
Authors: M. A. Stammes, S. L. Bugby, T. Porta, K. Pierzchalski, T. Devling, C. Otto et al.
Notes: Visible results
Defining the molecular pathology of pancreatic body and tail adenocarcinoma. BJS 2018; 105: e183-e191.
Authors: S. B. Dreyer, N. B. Jamieson, R. Upstill‐Goddard, P. J. Bailey, C. J. McKay, A. V. Biankin et al.
Notes: Worse genetic profile in tail